Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Immunotherapy × Dacarbazine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 62 Hodgkin Disease 46 Lymphoma 18 Sarcoma 10 Neoplasm Metastasis 9 Leiomyosarcoma 7 Skin Neoplasms 6 Neoplasms 5 Uveal Melanoma 4 Recurrence 3 Solitary Fibrous Tumors 2 Sarcoma, Synovial 2 Thyroid Neoplasms 1 Solid Tumor 1 Small Cell Lung Carcinoma 1 Skin Diseases 1 Sarcoma, Ewing 1 Sarcoma, Clear Cell 1 Sarcoma, Alveolar Soft Part 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Parathyroid Neoplasms 1 Osteosarcoma 1 Oligodendroglioma 1 Neurofibrosarcoma 1 Neuroendocrine Tumors 1 Neuroblastoma 1 Melanoma Neoplasms 1 Lung Neoplasms 1 Liposarcoma 1 Kidney Neoplasms 1

Interventions

tislelizumab 1 Oxaliplatin 1 Immunotherapy, Adoptive 1 Dacarbazine 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04225390 2026-02-10

PROMIT

University of Erlangen-Nürnberg Medical School

Phase 2 Completed

Immunotherapy

Data powered by HemOnc (CC BY 4.0) Colophon ⚡